CHMP recommends approval of Pedmarqsi in prevention of ototoxicity induced by cisplatin chemotherapy in children with solid tumours.- Fennec Pharma
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Pedmarqsi (sodium thiosulfate) from Fennec Pharmaceuticals, intended for the prevention of ototoxicity induced by cisplatin chemotherapy in children with solid tumours.
Pedmarqsi will be available as an 80 mg/ml solution for infusion. The active substance of Pedmarqsi is sodium thiosulfate (ATC code not yet assigned), an antidote with a mechanism of action that is not fully understood but is thought to include increasing levels of endogenous antioxidants, inhibition of intracellular oxidative stress and direct interaction with cisplatin to prevent cisplatin-induced damage to cochlear cells and associated hearing loss.
The benefit of Pedmarqsi is preventing cisplatin-induced hearing loss, as evaluated in a phase III, randomised, open-label study in children with standard-risk hepatoblastoma and treated with cisplatin alone or in combination with Pedmarqsi. The most common side effects are vomiting, nausea, hypernatraemia, hypophosphataemia and hypokalaemia.
The full indication is: Pedmarqsi is indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localised, non-metastatic, solid tumours.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins